JP2009502780A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009502780A5 JP2009502780A5 JP2008522796A JP2008522796A JP2009502780A5 JP 2009502780 A5 JP2009502780 A5 JP 2009502780A5 JP 2008522796 A JP2008522796 A JP 2008522796A JP 2008522796 A JP2008522796 A JP 2008522796A JP 2009502780 A5 JP2009502780 A5 JP 2009502780A5
- Authority
- JP
- Japan
- Prior art keywords
- quinolin
- pyrrolo
- amido
- pyridin
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 6-Methyl-pyridin-2-yl Chemical group 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70164105P | 2005-07-22 | 2005-07-22 | |
| US60/701,641 | 2005-07-22 | ||
| PCT/US2006/025377 WO2007018818A1 (en) | 2005-07-22 | 2006-06-29 | A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009502780A JP2009502780A (ja) | 2009-01-29 |
| JP2009502780A5 true JP2009502780A5 (cg-RX-API-DMAC7.html) | 2009-08-20 |
| JP5242391B2 JP5242391B2 (ja) | 2013-07-24 |
Family
ID=37450942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008522796A Expired - Fee Related JP5242391B2 (ja) | 2005-07-22 | 2006-06-29 | Tgf−ベータ阻害剤としてのピリジンキノリン置換ピロロ[1,2−b]ピラゾール一水和物 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7872020B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1910370B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5242391B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0613639A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2616196C (cg-RX-API-DMAC7.html) |
| DK (1) | DK1910370T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2542425T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20150474T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE025209T2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL188181A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2008001020A (cg-RX-API-DMAC7.html) |
| PL (1) | PL1910370T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT1910370E (cg-RX-API-DMAC7.html) |
| RS (1) | RS53999B1 (cg-RX-API-DMAC7.html) |
| SI (1) | SI1910370T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007018818A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR081810A1 (es) | 2010-04-07 | 2012-10-24 | Bayer Cropscience Ag | Piridinilpirazoles biciclicos |
| RU2612958C2 (ru) | 2011-07-13 | 2017-03-14 | Ск Кемикалз Ко., Лтд. | 2-пиридилзамещенные имидазолы в качестве ингибиторов alk5 и/или alk4 |
| EP2917365B1 (en) | 2012-11-12 | 2020-03-11 | Institució Catalana de Recerca i Estudis Avançats | Methods and kits for the prognosis of colorectal cancer |
| BR112015023261A2 (pt) | 2013-03-14 | 2017-07-18 | Massachusetts Inst Technology | composições e métodos para expansão e cultura de células-tronco epiteliais |
| CN107073042A (zh) | 2014-09-03 | 2017-08-18 | 布里格海姆妇女医院公司 | 用于产生内耳毛细胞来治疗听力损失的组合物、系统和方法 |
| WO2016123573A1 (en) | 2015-01-30 | 2016-08-04 | President And Fellows Of Harvard College | Peritumoral and intratumoral materials for cancer therapy |
| EP3277673B1 (en) | 2015-04-01 | 2022-05-04 | Rigel Pharmaceuticals, Inc. | Tgf-beta inhibitors |
| JP6980534B2 (ja) | 2015-06-25 | 2021-12-15 | ザ チルドレンズ メディカル センター コーポレーション | 造血幹細胞の増大、富化、および維持に関する方法および組成物 |
| US10450318B2 (en) | 2015-12-15 | 2019-10-22 | Bristol-Myers Squibb Company | CXCR4 receptor antagonists |
| CA3010610A1 (en) | 2016-01-08 | 2017-07-13 | The Brigham And Women's Hospital, Inc. | Production of differentiated enteroendocrine cells and insulin producing cells |
| US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
| US11260130B2 (en) | 2016-03-02 | 2022-03-01 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV |
| US10213511B2 (en) | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
| WO2017161001A1 (en) | 2016-03-15 | 2017-09-21 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion |
| US10604528B2 (en) | 2016-07-07 | 2020-03-31 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Galunisertib crystalline form, preparation method thereof and use thereof |
| WO2018068759A1 (zh) | 2016-10-14 | 2018-04-19 | 江苏恒瑞医药股份有限公司 | 五元杂芳环并桥环类衍生物、其制备方法及其在医药上的应用 |
| AU2017386417B2 (en) | 2016-12-30 | 2022-07-14 | Frequency Therapeutics, Inc. | 1H-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells |
| WO2018165979A1 (zh) * | 2017-03-17 | 2018-09-20 | 杭州领业医药科技有限公司 | 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的晶型及其制备方法和药物组合物 |
| WO2018170724A1 (zh) | 2017-03-21 | 2018-09-27 | 杭州领业医药科技有限公司 | 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的共晶,其制备方法和药物组合物 |
| WO2019042383A1 (zh) * | 2017-08-31 | 2019-03-07 | 苏州科睿思制药有限公司 | Galunisertib的晶型及其制备方法和用途 |
| WO2019105082A1 (zh) * | 2017-11-30 | 2019-06-06 | 苏州科睿思制药有限公司 | Galunisertib的晶型及其制备方法和用途 |
| WO2019137027A1 (zh) * | 2018-01-12 | 2019-07-18 | 苏州科睿思制药有限公司 | Galunisertib的晶型及其制备方法和用途 |
| ES3038913T3 (en) | 2018-03-20 | 2025-10-15 | Icahn School Med Mount Sinai | Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes |
| US20210254006A1 (en) | 2018-06-06 | 2021-08-19 | Ideaya Biosciences, Inc. | Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds |
| WO2020037326A1 (en) | 2018-08-17 | 2020-02-20 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by downregulating foxo |
| WO2020037323A1 (en) | 2018-08-17 | 2020-02-20 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by upregulating jag-1 |
| CA3124700A1 (en) | 2018-12-31 | 2020-07-09 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| CN115282280A (zh) * | 2022-08-12 | 2022-11-04 | 中国科学技术大学 | TGF-β1信号抑制剂的新用途 |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| GB202309553D0 (en) | 2023-06-24 | 2023-08-09 | Ucl Business Ltd | Compostions and uses thereof |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1397364T1 (sl) * | 2001-05-24 | 2007-12-31 | Lilly Co Eli | Novi pirolni derivati kot farmacevtske uäśinkovine |
| EP1567528A1 (en) * | 2002-11-21 | 2005-08-31 | Eli Lilly And Company | Mixed lineage kinase modulators |
| UA80571C2 (en) | 2002-11-22 | 2007-10-10 | Lilly Co Eli | Quinolinyl-pyrrolopyrazoles |
-
2006
- 2006-06-29 CA CA2616196A patent/CA2616196C/en not_active Expired - Fee Related
- 2006-06-29 PT PT67742809T patent/PT1910370E/pt unknown
- 2006-06-29 SI SI200631924T patent/SI1910370T1/sl unknown
- 2006-06-29 EP EP20060774280 patent/EP1910370B1/en not_active Expired - Lifetime
- 2006-06-29 PL PL06774280T patent/PL1910370T3/pl unknown
- 2006-06-29 HR HRP20150474TT patent/HRP20150474T1/hr unknown
- 2006-06-29 WO PCT/US2006/025377 patent/WO2007018818A1/en not_active Ceased
- 2006-06-29 DK DK06774280.9T patent/DK1910370T3/en active
- 2006-06-29 MX MX2008001020A patent/MX2008001020A/es active IP Right Grant
- 2006-06-29 ES ES06774280.9T patent/ES2542425T3/es not_active Expired - Lifetime
- 2006-06-29 RS RS20150319A patent/RS53999B1/sr unknown
- 2006-06-29 HU HUE06774280A patent/HUE025209T2/en unknown
- 2006-06-29 JP JP2008522796A patent/JP5242391B2/ja not_active Expired - Fee Related
- 2006-06-29 BR BRPI0613639-7A patent/BRPI0613639A2/pt not_active Application Discontinuation
- 2006-06-29 US US11/995,938 patent/US7872020B2/en not_active Expired - Fee Related
-
2007
- 2007-12-17 IL IL188181A patent/IL188181A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20151299T1 (hr) | Kristalni (r)-(e)-2-(4-(2-(5-(1-(3,5-diklorpiridin-4-il)etoksi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol i njegova upotreba kao inhibitora fgfr | |
| JP2011168587A5 (cg-RX-API-DMAC7.html) | ||
| FI2134702T4 (fi) | 6-[2-(metyylikarbamoyyli)fenyylisulfanyyli]-3-E-[2-(pyridiini-2-yyli)etenyyli]indatsolin kidemuotoja jotka soveltuvat nisäkkäiden poikkeavan solukasvun hoitamiseen | |
| WO2005046589A3 (en) | Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties | |
| WO2009066326A3 (en) | Improved process for the preparation of prasugrel and its pharmaceutically acceptable salts | |
| WO2010026436A3 (en) | 1,3, 4, 6, 7, 11b-hexahydro-benzo[alpha]quinolizines for the treatment of hyperkinetic movement and related disorders | |
| RU2007110026A (ru) | ПОЛИМОРФНЫЕ И АМОРФНАЯ ФОРМЫ ФОСФАТНОЙ СОЛИ 8-ФТОР-2-{4-[(МЕТИЛАМИНО)МЕТИЛ]ФЕНИЛ}-1,3,4,5-ТЕТРАГИДРО-6Н-АЗЕПИНО[5.4.3-cd]ИНДОЛ-6-ОНА | |
| WO2007076348A3 (en) | Azaindole inhibitors of aurora kinases | |
| WO2009080227A3 (en) | Pyrazole-carboxamide derivatives as p2y12 antagonists | |
| JP2017519027A5 (cg-RX-API-DMAC7.html) | ||
| WO2008044243A3 (en) | Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof | |
| WO2007048066A3 (en) | Pyrazolo-pyrimidines as casein kinase ii (ck2) modulators | |
| WO2009080226A3 (en) | Heterocyclic pyrazole-carboxamides as p2y12 antagonists | |
| JP2012512158A5 (cg-RX-API-DMAC7.html) | ||
| WO2008001195A3 (en) | Novel processes for the preparation of dpp iv inhibitors | |
| WO2008048867A3 (en) | Bicyclic heteroaromatic compounds | |
| CA2616196A1 (en) | A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor | |
| WO2010089510A3 (fr) | Dérivés d'azaspiranyl-alkylcarbamates d'hétérocycles à 5 chaînons, leur préparation et leur application en thérapeutique | |
| JP2005517696A5 (cg-RX-API-DMAC7.html) | ||
| WO2009149139A8 (en) | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | |
| WO2009013348A3 (en) | Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions | |
| WO2007081597A3 (en) | Peri condensed tricyclic compounds useful as antibacterial agents | |
| JP2020502224A5 (cg-RX-API-DMAC7.html) | ||
| JP2013514974A5 (cg-RX-API-DMAC7.html) | ||
| WO2009047499A3 (en) | Processes for the preparation of paliperidone and pharmaceutically acceptable salts thereof and intermediates for use in the processes |